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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S421withdrawal threshold (PWT: g) using calibrated Von Frey hairs) at 0, 3,
7, 9, 14, 16 and 20 days post-injection. Alterations in knee joint structure
(cartilage and synovium) were examined by macroscopic visualisation
of articular surfaces (Guingamp classiﬁcation), histology or immuno-
histochemistry. Differences between groups were analysed using
Kruskal Wallis test followed by post hoc Dunn’s test. Data are presented
as mean (95% conﬁdence interval). Data for correlations between pain
and pathology were obtained using pain behaviour scores observed at
day of sacriﬁce. Data are presented as Spearman’s correlation
coefﬁcients.




Weight bearing difference (%) 49.8 (14-85.5) 52.8 (4.78-101) 189 (118-261)* ++ n/a -0.44x
PWT (g) 282 (265-298) 187 (115-259)* 187 (160-215)** -0.44x n/a
Inﬂammation
Synovitis 0.7 (-0.2-1.6) 1.6 (0.9-2.4) 2.5 (2.1-2.9)** 0.27 -0.39
Macrophage area (%) 7.1 (2.9-11) 7.8 (5.1-11) 16 (11-22)* + 0.34 -0.21
Joint pathology
Macroscopic chondropathy 3.4 (1.8-5) 9.2 (7.4-11)** 11 (8.4-13)*** 0.44xx -0.28
Cartilage damage 0.5 (0.2-0.9) 2.2 (1.6-2.9)** 3.6 (1.3-5.9)*** 0.31 -0.51x
Chondrocyte morphology 0.4 (0.3-0.6) 2.1 (1.5-2.6)** 2.3 (1.9-2.6)** 0.15 -0.52x
Proteoglycan loss (Safranin-O-fast green) 2.0 [1.8-2.2) 2.4 (2.0-2.8)* 2.7 (2.4-2.9)** 0.07 -0.37
Proteoglycan loss (Alcian blue-PAS) 0.6 (0.4-0.8) 0.7 (0.38-1) 1.4 (1.1-1.8)*** ++ 0.15 0.07
Intra-articular injection of MIA produced marked changes in pain behaviour (increase in % weight bearing difference between left and right hind limb and decrease in PWT)
and pathology. MIA-induced changes in pain behaviour correlated with changes in macroscopic and microscopic pathology.
***p < 0.001 compared to saline control, ++p < 0.01 compared to 0.1 mg MIA and *p < 0.05 compared to saline control.Conclusions: Structural pathology and pain behaviour were dependent
on the dose of MIA used. Pain behaviour was associated with severity of
structural pathology. The 0.1 mg dose of MIA produced less severity in
both pathology and pain behaviour. Reduced mechanical PWT indi-
cating allodynia, in the absence of pronounced weight bearing asym-
metry may suggest that mechanisms other than ongoing nociceptive
input mediate distal allodynia in the low dose MIA model. Our results
show that central augmentation of pain is not restricted to late, struc-
turally severe OA following MIA injection in rats.
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THE EFFECT OF RESINIFERATOXIN PRETREATMENT ON PAIN
MEASURED BY DYNAMIC WEIGHT BEARING AND EVOKED PAIN
RESPONSES IN AN ACUTE INFLAMMATORY MURINE ARTHRITIS
MODEL
H.E. Krug y,z, M. Abdullah z, S. Funkenbusch y, C.W. Dorman y,
S.P. Frizelle y, M.L. Mahowald y,z. yVA Hlth.Care System, Minneapolis, MN,
USA; zUniv. of Minnesota, Minneapolis, MN, USA
Purpose: Activation of vanilloid receptors by intra-articular (IA) Cap-
saicin (CAP) injection normalizes Evoked Pain Scores (EPS) and
Dynamic Weight Bearing (DWB) measures in carrageenan-induced
acute inﬂammatory arthritis. Resiniferatoxin (RTX) is an ultrapotent
CAP analogue that has a similar mechanism of action, and may have
greater efﬁcacy on carrageenan-induced arthritis when administered
intra-articularly. We hypothesized that mice with acute arthritis
would have measurable changes in DWB and EPS due to joint pain,
and that these changes could be prevented by pre-treating with IA
RTX.
Methods: Acute inﬂammatory arthritis was produced in C57Bl6mice by
IA injection of 10 ml of 2.5% carrageenan into the left knee 3 hours prior
to pain behavior testing. Two groups of mice were injected with dif-
ferent doses of IA RTX (10 ml of 0.001% and 10 ml of 0.0003%) 7 days prior
to induction of arthritis. Similarly, another group of mice was injected
with 10 ml of 0.01% IA CAP 7 days prior to induction of arthritis. DWB
was measured with a Dynamic Weight Bearing apparatus (Bioseb,
Vitrolles, France). Evoked pain behavior was measured by tallying ﬁghts
þ vocalizations/1 min with repeated ﬁrm palpation of the knee.Results: Increased EPS and reduced DWB measures were clear and
reproducible indicators of pain in the affected limbs of arthritic mice.
Naïve mice demonstrated low EPS scores (1.01) and equal left to right
DWB ratios for weight (1.01) and time (1.00). Induction of acute
arthritis by IA Carrageenan resulted in a signiﬁcantly increased EPS
(6.25) and a signiﬁcant decrease in left to right DWB ratios for weight
(0.64) and time (0.89) when compared with controls. Pretreatment
with IA CAP 7 days prior to IA Carrageenan resulted in signiﬁcant
improvement in EPS (3.25) and near normalization of left to right
DWB ratios for weight (0.975) and time (1.00). Pretreatment with the
high dose and the low dose IA RTX 7 days prior to IA Carrageenan leadto signiﬁcantly improved EPS (1.5 & 1.5, respectively) and left to right
DWB ratios for weight (0.85 & 0.82, respectively) and time (0.99 &
0.96, respectively) when compared with the acute arthritis model. IA
administration of CAP alone and RTX alone did not have a signiﬁcant
impact on EPS or DWB ratios after 7 days. Immunohistochemical (IHC)
evaluation of substance P in the spinal cord dorsal horn demonstrated
some differences between naive nonarthritic mice and both arthritic
and RTX treated mice.
Conclusions: DWB and EPS are sensitive and speciﬁc for quantita-
tion of pain in murine arthritis models. IA Carrageenan admin-
istration resulted in a signiﬁcant increase in EPS and a signiﬁcant
decrease in DWB measures in the affected limb. IA RTX pretreat-
ment in these mice clearly improved pain measures as assessed by
EPS and DWB measures and these results were comparable to those
previously reported for IA CAP. IA Carrageenan and IA RTX seem to
have an enhancing effect on substance P in the dorsal horn as
determined by IHC. The potential advantages RTX may have over
CAP include a possibly lower therapeutic dose and longer duration
of effect. These factors represent important directions for future
studies.
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EFFECTIVENESS AND COST-EFFECTIVENESS OF A GROUP-BASED PAIN
SELF-MANAGEMENT INTERVENTION FOR PATIENTS UNDERGOING
TOTAL HIP REPLACEMENT: FEASIBILITY STUDY FOR A
RANDOMISED CONTROLLED TRIAL
V. Wylde, E. Marques, N. Artz, A. Blom, R. Gooberman-Hill. Univ. of
Bristol, Bristol, United Kingdom
Purpose: Total hip replacement (THR) is a common elective surgical
procedure and can be effective for reducing chronic pain. However,
waiting times for THR can be considerable, and patients often experi-
ence signiﬁcant pain during this time. A pain self-management inter-
vention may provide patients with the skills to enable them to manage
their pain and its impact more effectively during the wait for surgery.
However, studies of arthritis self-management programmes have faced
challenges because of low recruitment rates, poor intervention uptake,
and high attrition rates. Therefore, this study aimed to evaluate the
feasibility of a randomised controlled trial (RCT) to assess the effec-
tiveness and cost-effectiveness of a group-based pain self-management
course for patients undergoing THR and assess the acceptability of the
intervention. Speciﬁc objectives were to assess trial design, ascertain
recruitment and retention rates, identify barriers to participation, reﬁne
data collection methods, and evaluate uptake and patient satisfaction
with the course.
Methods: Patients listed for a THR at the Avon Orthopaedic Centre in
Bristol were sent a postal invitation about the study. After recruitment,
participants were randomised to attend a pain self-management course
plus standard care or standard care only using a computer-generated
randomisation system (Minim). The pain self-management course was
delivered by Arthritis Care and consisted of two half-day group sessions
prior to surgery and one full-day group session 2-4 months after sur-
gery. A structured course evaluation questionnaire was completed by
participants after the sessions. Outcomes assessment was by postal
questionnaire prior to surgery and 1-month, 3-months and 6-months
after surgery. Self-report resource use data were collected using a diary
prior to surgery and inclusion of resource use questions in the 3-month
and 6-month post-operative questionnaires. Brief telephone interviews
were conducted with consenting non-participants to explore barriers to
participation. NHS ethics approval was obtained (11/SW/0056) and
participants provided informed, written consent.
Results: Postal invitations were sent to 385 eligible patients and 88
patients consented to participate (23% recruitment rate). Participants
had a mean age of 66 years and 65% were female. Brief interviews with
57 non-participants revealed the most common reasons for non-par-
ticipation were perceptions about the intervention and difﬁculties in
getting to the hospital to attend the course. Of the 43 patients rando-
mised to the intervention group, 28 attended the pre-operative pain
self-management sessions and 11 attended the post-operative sessions.
Participant satisfaction with the course was high, and patients enjoyed
the group format of the course.Retention of participants was acceptable,
with 83% completing follow-up. Questionnaire return rates were high at
all assessment times (76-93%), with the exception of the pre-operative
resource use diary (35%). Completion rates for the resource use ques-
tions varied by category and allowed for an economic perspective from
the health and social care payer to be taken.
Conclusion: Undertaking feasibility work for a RCT is labour-intensive;
however this study highlights the importance of conducting such work.
Postal recruitment resulted in a low recruitment rate and brief inter-
views with non-participants provided valuable information on barriers
to participation. Embedding collection of resource use data within
questionnaires resulted in higher completion rates than using resource
use diaries. While patients who attended the course gave positive
feedback, attendance was low. Findings from this feasibility study
enable us to design successful deﬁnitive group-based RCTs in the future,
ensuring the delivery of effectiveness and cost-effectiveness evidence
to inform service provision for patients undergoing THR.761
CAPSAICIN TREATMENT FOR OSTEOARTHRITIS PAIN: A META-
ANALYSIS
L. Laslett, G. Jones. Univ. of Tasmania, HOBART, Australia
Background: Capsaicin appears to be effective for osteoarthritis pain
but it is uncertain whether the effect has a dose response, is consistent
across joints, or changes over time.
Purpose: To perform a quantitative overview the use of topical cap-
saicin in the therapy of painful osteoarthritis (OA) in adults, and to
assess whether effects vary by formulation strength, joint site, or
treatment duration.
Methods: Literature databases (PubMed, EMBASE, ISI Web of Knowl-
edge) were searched for randomized controlled trials for use of topical
capsaicin (or capsaicin-like therapies) in OA using the keywords:
“capsaicin”, “osteoarthritis” “double-blind method”, “randomized con-
trolled trial [publication type]” or “controlled clinical trial [publication
type]” up to 2012. Studies not in English were excluded. Trials were
compared for pain scores (assessed using visual analog scales (VAS)),
patient global evaluation of treatment effectiveness and application site
burning using standardised mean differences (SMD), using RevMan.
Results: Five double-blind randomized controlled trials and one case-
crossover trial were identiﬁed, testing topical capsaicin four times daily.
Formulations ranged from 0.025% - 0.075%, and trial durations from 4-
12 weeks. Trials assessed OA of the knee (n¼ 3), hand (n¼ 1), and a mix
of joints (n ¼ 2). Patients were typically required to have at least
moderate pain and either radiologically or clinically deﬁned OA, or both.
Treatment efﬁcacy of capsaicin (compared to placebo) for change in VAS
pain score was moderate, at 0.44 (95% CI 0.25-0.62) over 4 weeks of
treatment. There was no heterogeneity between studies, indicating no
between-study differences, including effect of OA site or treatment
concentration. There was disagreement on effectiveness over time. Two
studies reported treatment beyond 4 weeks, with the ﬁrst study
reporting an effect size of -9mm after 12 weeks, with the maximum
difference between groups occurring at 4 weeks. The second study
reported that between-group differences increased over time, up to 20
weeks.
Capsaicin was reported as being safe and well-tolerated, with no sys-
temic toxicity. The most common side effect reported was mild appli-
cation site burning, affecting 35-100% of capsaicin-treated patients; the
risk ratio was 4.22 (95% CI 3.25-5.48), reported in 5 trials. Incidence of
burning peaked in week 1, with incidence rates declining over time,
plateauing from weeks 2-12.
Conclusions: Topical capsaicin treatment four times daily is moderately
effective in reducing pain intensity up to 20 weeks regardless of site of
application anddose inpatientswith at leastmoderatepain and clinical or
radiologically deﬁned OA. Capsaicin treatment is also generally well tol-
erated, suggesting that capsaicin should be used early in theOA treatment
algorithm, especially for superﬁcial joints such as the hand and knee.
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EFFECT OF TISSUEGENE-C, A NOVEL CELL AND GENE THERAPY, ON
PAIN AND CARTILAGE REGENERATION IN A RAT OSTEOARTHRITIS
MODEL
B. Lee, K. Choi, H. Lee, D-W. Lee, H. Lee, H. Choi, S. Kim. Kolon Life Sci.,
Inc., Gwacheon-si, Republic of Korea
Purpose: TissueGene-C(TG-C) has been developed as a cell and gene
therapy for patients withosteoarthritis. It is a mixture of non-trans-
duced human chondrocytes (hChonJ) and genetically modiﬁed chon-
drocytes expressing TGF-b1 (hChonJb#7). Phase 2b clinical trials have
shown that TG-C signiﬁcantly improved IKDC and 100 mm VAS scores
over placebo when administered to the knee joints of osteoarthritic
patients. In this study, a rat model of osteoarthritis was used to identify
the role of individual components of TG-C.
Methods: A rat model of osteoarthritis was induced by injection of
monosodium iodoacetate (MIA) into the left knee joint, which resulted
